These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27929207)

  • 1. Rivaroxaban vs. Warfarin for Anticoagulation in Patients with Atrial Fibrillation Undergoing Ablation and Cardioversion.
    Hawks MK; Bryce C
    Am Fam Physician; 2016 Oct; 94(7):Online. PubMed ID: 27929207
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
    Di Fusco SA; Colivicchi F; Aspromonte N; Tubaro M; Aiello A; Santini M
    Monaldi Arch Chest Dis; 2017 May; 87(1):805. PubMed ID: 28635196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 10. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation.
    Zhu J; Gao RJ; Liu Q; Jiang RH; Yu L; Sun YX; Zhang P; Lin JW; Ye Y; Zhang ZW; Chen SQ; Cheng H; Sheng X; Jiang CY
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):946-954. PubMed ID: 29119732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials].
    Akıllı R; Demir M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):15-23. PubMed ID: 28947726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-specific oral anticoagulants in patients undergoing cardioversion.
    Law EH; Gordon W
    Am J Health Syst Pharm; 2014 Jul; 71(14):1171-6. PubMed ID: 24973374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct current cardioversion of atrial fibrillation--the next 40 years.
    Manning WJ; Zimetbaum PJ
    Mayo Clin Proc; 2002 Sep; 77(9):895-6. PubMed ID: 12233920
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardioversion of atrial arrhythmias: audit of anticoagulation management.
    Mayet J; Wasan B; Sutton GC
    J R Coll Physicians Lond; 1997; 31(3):313-6. PubMed ID: 9192336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for patients with atrial fibrillation. Warfarin should be given for up to one year after successful cardioversion.
    Berry C; McMurray J
    BMJ; 2000 Sep; 321(7261):639. PubMed ID: 11023332
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
    Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
    G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.